* Orthofix Medical Inc OFIX.OQ OFIX.O is expected
to show a
rise in quarterly revenue when it reports results on May 9.
* The Lewisville Texas-based company is expected to report
a
58.3% increase in revenue to $168.457 million from $106.42
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. The company's guidance on
March 6 2023, for the period ended March 31, was for revenue
between $166.00 million and $170.00 million.
* Refinitiv's mean analyst estimate for Orthofix Medical
Inc is
for a loss of 51 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Orthofix
Medical
Inc is $37, above its last closing price of $18.48.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.34 0.10 0.19 Beat 83.9
Sep. 30 2022 0.13 0.12 0.13 Beat 11.4
Jun. 30 2022 0.10 0.10 0.08 Missed -20
Mar. 31 2022 0.10 0.09 -0.10 Missed -215.4
Dec. 0.13 0.13 0.27 Beat 107.7
31 2021
Sep. 30 2021 0.11 0.11 0.10 Missed -10.4
Jun. 30 2021 0.13 0.11 0.32 Beat 190.9
Mar. 31 2021 0.01 0.02 0.17 Beat 709.5
This summary was machine generated May 6 at 02:03 GMT. All
figures in US dollars unless otherwise stated